A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of type A and type B alcoholism

Journal of Clinical Psychopharmacology

Volumn 27, Issue 4, 2007, Pages 344-351

  Kampman, Kyle M ^a,c   Pettinati, Helen M ^a   Lynch, Kevin G ^a   Whittingham, Tom ^a   Macfadden, Wayne ^b   Dackis, Charles ^a   Tirado, Carlos ^a   Oslin, David W ^a   Sparkman, Thorne ^a   O'Brien, Charles P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; QUETIAPINE;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WITHDRAWAL SYNDROME;

ADULT; ALCOHOLISM; ANTIPSYCHOTIC AGENTS; ANXIETY; COMORBIDITY; DEPRESSION; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SURVIVAL ANALYSIS; TEMPERANCE; TREATMENT OUTCOME;

EID: 34447520132     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3180ca86e5     Document Type: Article

References (45)

1. Anton RF. Pharmacological approaches to the management of alcoholism. J Clin Psychiatry. 2001;62:11-17.
2. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25:1335-1341.
3. Suh JJ, Pettinati HM, Kampman KM, et al. The status of disulfiram a half century later. J Clin Psychopharmacol. 2006;26:290-302.
4. Babor TF, Hofmann M, DelBoca FK, et al. Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry. 1992;49:599-608.
5. Babor TF, Dolinsky ZS, Rounsaville B, et al. Unitary versus multidimensional models of alcoholism treatment outcome: an empirical study. J Stud Alcohol. 1988;49:167-177.
6. Kranzler HR, Burleson JA, Brown J, et al. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996;20:1534-1541.
7. Pettinati HM, Volpicelli JR, Kranzler HR, et al. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000;24:1041-1049.
8. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
9. Koob G, Roberts A. Brain reward circuits in alcoholism. CNS Spectr. 1999;4:23-37.
10. Yoshimoto K, McBride WJ, Lumeng L, et al. Ethanol enhances the release of dopamine and serotonin in the nucleus accumbens of HAD and LAD lines of rats. Alcohol Clin Exp Res. 1992;16:781-785.
11. Imperato A, Di Chiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther. 1986;239:219-228.
12. Mereu G, Fadda F, Gessa GL. Ethanol stimulates the firing rate of nigral dopaminergic neurons in unanesthetized rats. Brain Res. 1984;292:63-69.
13. Noble EP. Alcoholism and the dopaminergic system. Addict Biol. 1996;1:333-348.
14. Modell JG, Mountz JM, Glaser FB, et al. Effect of haloperidol on measures of craving and impaired control in alcoholic subjects. Alcohol Clin Exp Res. 1993;17:234-240.
15. Hutchison KE, Swift R, Rohsenow DJ, et al. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl). 2001;155:27-34.
16. Hutchison KE, Ray L, Sandman E, et al. The effects of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006;31:1310-1317.
17. Pettinati HM, Oslin D, Decker K. Role of serotonin and serotonin-selective pharmacotherapy in alcohol dependence. CNS Spectr. 2000;5:33-46.
18. Guardia J, Segura L, Gonzalvo B, et al. A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res. 2004;28:736-745.
19. Scheller-Gilkey G, Woolwine B, Cooper I, et al. Relationship of clinical symptoms and substance use in schizophrenia patients on conventional and atypical antipsychotics. Am J drug Alcohol Abuse. 2003;29:553-566.
20. Green AI, Burgess ES, Dawson R, et al. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 2003;60:81-85.
21. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26:441-449.
22. Kalyoncu A, Mirsal H, Pektas O, et al. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anticraving effect? J Psychopharmacol. 2005;19:301-305.
23. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl). 1993;112:285-292.
24. Monnelly EP, Ciraulo DA, Knapp C, et al. Quetiapine for the treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24:532-535.
25. Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci. 2004;29:452-457.
26. Riedel M, Muller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2005;255:432-437.
27. Larmo I, Nayer AD, Windhager E, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol. Hum Psychopharmacol. 2005;20:573-581.
28. Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar). Br J Addict. 1989;84:1353-1357.
29. First MB, Spitzer RL, Gibbon M , et al. Structured Clinical Interview for DSM-IV Axis I Disorders. Patient Edition (SCID-IP, Version 2.0) ed. New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
30. Volpicelli JR, Pettinati HM, McLellan AT, et al. Enhanced Medication and Treatment Adherence for Addiction Treatment: The Brenda Model. New York: Guilford Press; 2001.
31. Sobell LC, Sobell MB. Alcohol Timeline Followback Users' Manual. Toronto: Addiction Research Foundation; 1995.
32. Sobell LC, Toneatto T, Sobell MB. Behavioral assessment and treatment planning for alcohol, tobacco, and other drug problems: Current status with an emphasis on clinical applications. Behav Ther. 1994;25:533-580.
33. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199-213.
34. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
35. Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res. 1999;23:1289-1295.
36. Pettinati H, Volpicelli J, Pierce J, et al. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis. 2000;19:71-83.
37. Diggle PJ, Kenward MG. Informative dropout in longitudinal data analysis. Appl Stat. 1994;43:43-93 [with Discussion].
38. Epstein EE, Labouvie E, McCrady BS, et al. A multi-site study of alcohol subtypes: classification and overlap of unidimensional and multi-dimensional typologies. Addiction. 2002;97:1041-1053.
39. Ball SA, Jaffe AJ, Crouse-Artus MS, et al. Multidimensional subtypes and treatment outcome in first-time DWI offenders. Addict Behav. 2000;25:167-181.
40. Yoshino A, Kato M. Prediction of 3-year outcome of treated alcoholics by an empirically derived multivariate typology. Am J Psychiatry. 1996;153:829-830.
41. Meyers RD, Lankford MF, Bjork A. 5-HT2 receptor blockade by amperozide suppresses ethanol drinking in genetically preferring rats. Pharmacol Biochem Behav. 1993;45:741-747.
42. Meyers RD, Lankford MF. Suppression of alcohol preference in high alcohol drinking rats. Neuropsychopharmacology. 1996;14:139-149.
43. Gongwer MA, Murphy JM, McBride WJ, et al. Regional brain contents of serotonin, dopamine and there metabolites in selectively bred high- and low-alcohol drinking lines of rats. Alcohol. 1989;6:317-320.
44. Wiesback GA, Weijers HG, Chick J, et al. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Alcohol Clin Exp Res. 1999;23:230-235.
45. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000;284:963-971.